{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:35:47Z","timestamp":1790847347700,"version":"4.1.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Central nervous system lymphomas (CNSL) display remarkable clinical heterogeneity, yet accurate prediction of outcomes remains challenging. The IPCG criteria are widely used in routine practice for the assessment of treatment response. However, the value of the IPCG criteria for ultimate outcome prediction is largely unclear, mainly due to the uncertainty in delineating complete from partial responses during and after treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We explored various MRI features including semi-automated 3D tumor volume measurements at different disease milestones and their association with survival in 93 CNSL patients undergoing curative-intent treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At diagnosis, patients with more than 3 lymphoma lesions, periventricular involvement, and high 3D tumor volumes showed significantly unfavorable PFS and OS. At first interim MRI during treatment, the IPCG criteria failed to discriminate outcomes in responding patients. Therefore, we randomized these patients into training and validation cohorts to investigate whether 3D tumor volumetry could improve outcome prediction. We identified a 3D tumor volume reduction of \u226597% as the optimal threshold for risk stratification (=3D early response, 3D_ER). Applied to the validation cohort, patients achieving 3D_ER had significantly superior outcomes. In multivariate analyses, 3D_ER was independently prognostic of PFS and OS. Finally, we leveraged prognostic information from 3D MRI features and circulating biomarkers to build a composite metric that further improved outcome prediction in CNSL.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We developed semi-automated 3D tumor volume measurements as strong and independent early predictors of clinical outcomes in CNSL patients. These radiologic features could help improve risk stratification and help guide future treatment approaches.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/neuonc\/noad177","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T05:33:27Z","timestamp":1694669607000},"page":"374-386","source":"Crossref","is-referenced-by-count":10,"title":["Improved early outcome prediction by MRI-based 3D tumor volume assessment in patients with CNS lymphomas"],"prefix":"10.1093","volume":"26","author":[{"given":"Eliza M","family":"Lauer","sequence":"first","affiliation":[{"name":"Department of Medicine I, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg , Freiburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Riegler","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg , Freiburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurik A","family":"Mutter","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg , Freiburg , Germany"},{"name":"Divisions of Oncology and Hematology, Department of Medicine, Stanford University , Stanford, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan K","family":"Alig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Bleul","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg , Freiburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Kuehn","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg , Freiburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavanya","family":"Ranganathan","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg , Freiburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Klingler","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg , Freiburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Demerath","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, Medical Center, University of Freiburg , Freiburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urs","family":"W\u00fcrtemberger","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, Medical Center, University of Freiburg , Freiburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5881-6043","authenticated-orcid":false,"given":"Alexander","family":"Rau","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, Medical Center, University of Freiburg , Freiburg , Germany"},{"name":"Department of Radiology, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg , Freiburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Wei\u00df","sequence":"additional","affiliation":[{"name":"Department of Radiology, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg , Freiburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Eisenblaetter","sequence":"additional","affiliation":[{"name":"Department of Radiology, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg , Freiburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7460-3942","authenticated-orcid":false,"given":"Fabian","family":"Bamberg","sequence":"additional","affiliation":[{"name":"Department of Radiology, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg , Freiburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0349-1955","authenticated-orcid":false,"given":"Marco","family":"Prinz","sequence":"additional","affiliation":[{"name":"Institute of Neuropathology, Medical Faculty, University of Freiburg , Freiburg , Germany"},{"name":"Center for Basics in NeuroModulation (NeuroModulBasics), Faculty of Medicine, University of Freiburg , Freiburg , Germany"},{"name":"Signalling Research Centres BIOSS and CIBSS, University of Freiburg , Freiburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Finke","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg , Freiburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justus","family":"Duyster","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg , Freiburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Illerhaus","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology and Palliative Care, Klinikum Stuttgart , Stuttgart , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Diehn","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stanford School of Medicine , Stanford, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ash A","family":"Alizadeh","sequence":"additional","affiliation":[{"name":"Divisions of Oncology and Hematology, Department of Medicine, Stanford University , Stanford, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Schorb","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg , Freiburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C","family":"Reinacher","sequence":"additional","affiliation":[{"name":"Department of Stereotactic and Functional Neurosurgery, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg , Freiburg , Germany"},{"name":"Fraunhofer Institute for Laser Technology (ILT) , Aachen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9635-5487","authenticated-orcid":false,"given":"Florian","family":"Scherer","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg , Freiburg , Germany"},{"name":"German Cancer Consortium (DKTK) Partner Cite Freiburg and German Cancer Research Center (DKFZ) , Heidelberg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,15]]},"reference":[{"issue":"11","key":"2024020218233089900_CIT0001","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood."},{"issue":"5","key":"2024020218233089900_CIT0002","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","article-title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial","volume":"3","author":"Ferreri","year":"2016","journal-title":"Lancet Haematol"},{"issue":"25","key":"2024020218233089900_CIT0003","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2012.46.9957","article-title":"Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)","volume":"31","author":"Rubenstein","year":"2013","journal-title":"J Clin Oncol."},{"issue":"14","key":"2024020218233089900_CIT0004","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1200\/JCO.2015.64.8634","article-title":"Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG oncology RTOG 0227","volume":"34","author":"Glass","year":"2016","journal-title":"J Clin Oncol."},{"issue":"14","key":"2024020218233089900_CIT0005","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/bloodadvances.2020002064","article-title":"High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study","volume":"4","author":"Schorb","year":"2020","journal-title":"Blood Adv."},{"issue":"3","key":"2024020218233089900_CIT0006","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/bjh.15661","article-title":"Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma","volume":"184","author":"Fox","year":"2019","journal-title":"Br J Haematol."},{"issue":"22","key":"2024020218233089900_CIT0007","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"J Clin Oncol."},{"issue":"3","key":"2024020218233089900_CIT0008","first-page":"422","article-title":"Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial","volume":"19","author":"Tabouret","year":"2017","journal-title":"Neuro Oncol. 03 01"},{"issue":"1","key":"2024020218233089900_CIT0009","first-page":"vdab007","article-title":"Extent of radiological response does not reflect survival in primary central nervous system lymphoma","volume":"3","author":"van der Meulen","year":"2021","journal-title":"Neurooncol Adv."},{"issue":"2","key":"2024020218233089900_CIT0010","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00277-013-1853-7","article-title":"Early response to high-dose methotrexate, vincristine, and procarbazine chemotherapy-adapted strategy for primary CNS lymphoma: no consolidation therapy for patients achieving early complete response","volume":"93","author":"Kim","year":"2014","journal-title":"Ann Hematol."},{"issue":"7","key":"2024020218233089900_CIT0011","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/neuonc\/noab020","article-title":"Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG)","volume":"23","author":"Barajas","year":"2021","journal-title":"Neuro Oncol."},{"issue":"6","key":"2024020218233089900_CIT0012","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/neuonc\/noaa030","article-title":"Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases","volume":"22","author":"Kaufmann","year":"2020","journal-title":"Neuro Oncol."},{"issue":"9","key":"2024020218233089900_CIT0013","first-page":"1188","article-title":"Consensus recommendations for a standardized brain tumor imaging protocol in clinical trials","volume":"17","author":"Ellingson","year":"2015","journal-title":"Neuro Oncol"},{"issue":"4","key":"2024020218233089900_CIT0014","first-page":"770","article-title":"Measurement of tumor \u201csize\u201d in recurrent malignant glioma: 1D, 2D, or 3D","volume":"26","author":"Dempsey","year":"2005","journal-title":"AJNR Am J Neuroradiol."},{"issue":"364","key":"2024020218233089900_CIT0015","doi-asserted-by":"crossref","first-page":"364ra","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci Transl Med."},{"issue":"9","key":"2024020218233089900_CIT0016","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1200\/JCO.22.00826","article-title":"Circulating tumor DNA profiling for detection, risk stratification, and classification of brain lymphomas","volume":"41","author":"Mutter","year":"2023","journal-title":"J Clin Oncol."},{"issue":"9","key":"2024020218233089900_CIT0017","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1038\/s41375-022-01618-w","article-title":"Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research","volume":"36","author":"Lauer","year":"2022","journal-title":"Leukemia."},{"issue":"3","key":"2024020218233089900_CIT0018","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2019.06.011","article-title":"Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction","volume":"178","author":"Kurtz","year":"2019","journal-title":"Cell."},{"issue":"28","key":"2024020218233089900_CIT0019","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-Cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J Clin Oncol."},{"issue":"5","key":"2024020218233089900_CIT0020","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol."},{"issue":"14","key":"2024020218233089900_CIT0021","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1182\/blood-2016-05-719641","article-title":"Diffuse large B-cell lymphoma genotyping on the liquid biopsy","volume":"129","author":"Rossi","year":"2017","journal-title":"Blood."},{"issue":"29","key":"2024020218233089900_CIT0022","doi-asserted-by":"crossref","first-page":"48157","DOI":"10.18632\/oncotarget.18325","article-title":"Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma","volume":"8","author":"Fontanilles","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"2024020218233089900_CIT0023","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/bjh.17357","article-title":"MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study","volume":"193","author":"Ferreri","year":"2021","journal-title":"Br J Haematol."},{"issue":"2","key":"2024020218233089900_CIT0024","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/bjh.18539","article-title":"Management of secondary central nervous system lymphoma","volume":"200","author":"Cwynarski","year":"2023","journal-title":"Br J Haematol."},{"issue":"25","key":"2024020218233089900_CIT0025","first-page":"419","article-title":"The diagnosis and treatment of primary CNS lymphoma","volume":"115","author":"von Baumgarten","year":"2018","journal-title":"Dtsch Arztebl Int."},{"issue":"8","key":"2024020218233089900_CIT0026","doi-asserted-by":"crossref","first-page":"e388","DOI":"10.1016\/S2352-3026(16)30050-3","article-title":"High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial","volume":"3","author":"Illerhaus","year":"2016","journal-title":"Lancet Haematol"},{"issue":"1","key":"2024020218233089900_CIT0027","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12885-016-2311-4","article-title":"High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma\u2014a randomized phase III trial (MATRix). Clinical Trial, Phase III randomized controlled trial research support, non-U.S. Gov\u2019t","volume":"16","author":"Schorb","year":"2016","journal-title":"BMC Cancer"},{"issue":"4","key":"2024020218233089900_CIT0028","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/leu.2016.334","article-title":"High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)","volume":"31","author":"Fritsch","year":"2017","journal-title":"Leukemia."},{"issue":"2","key":"2024020218233089900_CIT0029","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1200\/JCO.2003.09.139","article-title":"Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience","volume":"21","author":"Ferreri","year":"2003","journal-title":"J Clin Oncol."},{"issue":"3","key":"2024020218233089900_CIT0030","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.neuroimage.2006.01.015","article-title":"User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability","volume":"31","author":"Yushkevich","year":"2006","journal-title":"Neuroimage."},{"issue":"5","key":"2024020218233089900_CIT0031","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol."},{"issue":"7802","key":"2024020218233089900_CIT0032","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41586-020-2140-0","article-title":"Integrating genomic features for non-invasive early lung cancer detection","volume":"580","author":"Chabon","year":"2020","journal-title":"Nature."},{"issue":"4","key":"2024020218233089900_CIT0033","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.tig.2023.01.004","article-title":"Bridging biological cfDNA features and machine learning approaches","volume":"39","author":"Moser","year":"2023","journal-title":"Trends Genet."},{"issue":"5","key":"2024020218233089900_CIT0034","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood-2018-09-875732","article-title":"Phase 1b trial of an ibrutinib-based combination therapy in recurrent\/refractory CNS lymphoma","volume":"133","author":"Grommes","year":"2019","journal-title":"Blood."},{"issue":"3","key":"2024020218233089900_CIT0035","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.seminhematol.2023.06.007","article-title":"Clinical applications of circulating tumor DNA in central nervous system lymphoma","volume":"60","author":"Foerster","year":"2023","journal-title":"Semin Hematol."},{"key":"2024020218233089900_CIT0036","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2019.05.024","article-title":"Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II \u201cproof-of-concept\u201d iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network","volume":"117","author":"Soussain","year":"08 2019","journal-title":"Eur J Cancer."},{"issue":"4","key":"2024020218233089900_CIT0037","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/annonc\/mdz032","article-title":"Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed\/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective \u201cproof of concept\u201d phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)","volume":"30","author":"Ghesquieres","year":"2019","journal-title":"Ann Oncol."},{"issue":"13","key":"2024020218233089900_CIT0038","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/bloodadvances.2017014845","article-title":"Phase 1 investigation of lenalidomide\/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma","volume":"2","author":"Rubenstein","year":"2018","journal-title":"Blood Adv."},{"issue":"Suppl. 1","key":"2024020218233089900_CIT0039","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1182\/blood-2021-148444","article-title":"Tisagenlecleucel demonstrates safety, efficacy and CNS trafficking in primary CNS lymphoma","volume":"138","author":"Frigault","year":"2021","journal-title":"Blood."},{"issue":"5","key":"2024020218233089900_CIT0040","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S1470-2045(19)30098-1","article-title":"Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study","volume":"20","author":"Kickingereder","year":"2019","journal-title":"Lancet Oncol."},{"issue":"1","key":"2024020218233089900_CIT0041","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3174\/ajnr.A3165","article-title":"Combined diffusion and perfusion MR imaging as biomarkers of prognosis in immunocompetent patients with primary central nervous system lymphoma","volume":"34","author":"Valles","year":"2013","journal-title":"AJNR Am J Neuroradiol."},{"issue":"2","key":"2024020218233089900_CIT0042","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/00004728-199903000-00011","article-title":"Perfusion-sensitive MRI of cerebral lymphomas: a preliminary report","volume":"23","author":"Sugahara","year":"1999","journal-title":"J Comput Assist Tomogr."},{"issue":"1","key":"2024020218233089900_CIT0043","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3174\/ajnr.A1750","article-title":"Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma","volume":"31","author":"Barajas","year":"2010","journal-title":"AJNR Am J Neuroradiol."},{"issue":"4","key":"2024020218233089900_CIT0044","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1158\/1078-0432.CCR-11-0625","article-title":"Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI","volume":"18","author":"Wieduwilt","year":"2012","journal-title":"Clin Cancer Res."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noad177\/51856705\/noad177.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/26\/2\/374\/56549312\/noad177.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/26\/2\/374\/56549312\/noad177.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T18:34:47Z","timestamp":1706898887000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/26\/2\/374\/7274855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,15]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,9,15]]},"published-print":{"date-parts":[[2024,2,2]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noad177","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2,1]]},"published":{"date-parts":[[2023,9,15]]}}}